| In millions, except per share items | Jun-30-23 | Jun-05-23 | Mar-31-23 | Mar-05-23 | Jun-30-22 | Jun-05-22 | Mar-31-22 | Mar-05-22 |
| | 10-Q | 8-K | 10-Q | 8-K | 10-Q | 8-K | 10-Q | 8-K |
| Revenues: |
| R&D and Commercialization Activities for Zimberelimab | 1.0 | | | | 1.0 | | | |
| Access rights and option continuation periods | 9.0 | | 8.0 | | 9.0 | | 8.0 | |
| Gilead | 7.0 | | 8.0 | | 13.0 | | 16.0 | |
| R&D activities for Domvanalimab | 1.0 | | 1.0 | | 1.0 | | 1.0 | |
| Other | 11.0 | | 8.0 | | 3.0 | | | |
| Total revenues [+] | 29.0 | 29.0 | 25.0 | 25.0 | 27.0 | 27.0 | 18.0 | 18.0 |
| Royalties | | 84.0 | | 81.0 | | 70.0 | | 61.0 |
| Revenue growth [+] | 7.4% | 7.4% | 38.9% | 38.9% | 185.4% | | 90.3% | |
| Gilead | -46.2% | | -50.1% | | | | | |
| Cost of goods sold | 0.0 | 112.0 | 0.0 | 81.0 | 0.0 | 96.0 | 0.0 | 61.0 |
| Gross profit | 29.0 | -83.0 | 25.0 | -56.0 | 27.0 | -69.0 | 18.0 | -43.0 |
| Gross margin | 100.0% | -286.2% | 100.0% | -224.0% | 100.0% | -255.6% | 100.0% | -238.9% |
| Selling, general and administrative [+] | 28.0 | 28.0 | 30.0 | 30.0 | 26.0 | 26.0 | 24.0 | 24.0 |
| General and administrative | 28.0 | 28.0 | 30.0 | 30.0 | 26.0 | 26.0 | 24.0 | 24.0 |
| Research and development | 84.0 | | 81.0 | | 70.0 | | 61.0 | |
| Equity in earnings | | | | | | | | |
| Other operating expenses | | -28.0 | | | | -26.0 | | |
| EBITDA [+] | -81.0 | | -84.0 | | -67.0 | | -66.0 | |
| EBITDA growth | 20.9% | 20.3% | 27.3% | 28.4% | -11.0% | | -8.3% | |
| EBITDA margin | -279.3% | -286.2% | -336.0% | -344.0% | -248.1% | -255.6% | -366.7% | -372.2% |
| Depreciation and amortization | 2.0 | | 2.0 | | 2.0 | | 1.0 | |
| EBIT [+] | -83.0 | -83.0 | -86.0 | -86.0 | -69.0 | -69.0 | -67.0 | -67.0 |
| EBIT growth | 20.3% | 20.3% | 28.4% | 28.4% | -9.4% | | -7.9% | |
| EBIT margin | -286.2% | -286.2% | -344.0% | -344.0% | -255.6% | -255.6% | -372.2% | -372.2% |
| Interest income | 9.0 | | 9.0 | | 3.0 | | | |
| Interest income | 9.0 | | 9.0 | | 3.0 | | | |
| Other income (expense), net | | 83.0 | -1.0 | 4.0 | -1.0 | 69.0 | | -2.0 |
| Pre-tax income | -74.0 | 0.0 | -78.0 | -82.0 | -67.0 | 0.0 | -67.0 | -69.0 |
| Income taxes | 1.0 | 0.0 | 2.0 | -2.0 | 0.0 | 0.0 | 1.0 | -1.0 |
| Tax rate | | | | 2.4% | 0.0% | | | 1.4% |
| Net income | -75.0 | 0.0 | -80.0 | -80.0 | -67.0 | 0.0 | -68.0 | -68.0 |
| Net margin | -258.6% | 0.0% | -320.0% | -320.0% | -248.1% | 0.0% | -377.8% | -377.8% |
| |
| Basic EPS [+] | ($1.02) | | ($1.10) | $73.00 | ($0.93) | | ($0.96) | $71.20 |
| Growth | 9.8% | | 14.7% | 2.5% | -14.3% | | -11.7% | |
| Diluted EPS [+] | ($1.02) | | ($1.10) | ($73.00) | ($0.93) | | ($0.96) | ($71.20) |
| Growth | 9.8% | | 14.7% | 2.5% | -14.3% | | -11.7% | |
| |
| Shares outstanding (basic) [+] | 73.2 | | 73.0 | -1.1 | 71.8 | | 71.2 | -1.0 |
| Growth | 1.9% | | 2.5% | 14.7% | 2.9% | | 6.1% | |
| Shares outstanding (diluted) [+] | 73.2 | | 73.0 | 1.1 | 71.8 | | 71.2 | 1.0 |
| Growth | 1.9% | | 2.5% | 14.7% | 2.9% | | 6.1% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |